Abstract
Background: Intravenous iron and erythropoietin have been shown to be effective in Crohn’s disease-associated anemia. The aim of this study was to test the sequential treatment of anemia in ulcerative colitis with intravenous iron in the first phase and erythropoietin in the second. Patients and Methods: Twenty patients with ulcerative colitis-associated anemia (hemoglobin ≤10.5 g/dl) entered this open-label trial. In the first phase all patients received intravenous iron saccharate for 8 weeks. A response was defined as an increase in hemoglobin ≥2.0 g/dl; a final hemoglobin >10.5 g/dl was regarded as full response, ≤10.5 g/dl as partial response. A hemoglobin increase <2.0 g/dl was regarded as nonresponse. In the second phase (n = 4) erythropoietin was initiated in patients without response. Patients with partial response were continued on iron saccharate for another 8 weeks. Results: During the first phase the hemoglobin increased from 8.3 to 11.9 g/dl (mean hemoglobin difference 3.6 ± 2.3 g/dl, p < 0.001). Fifteen patients (75%) showed a full response (mean hemoglobin difference 4.5 ± 1.5 g/dl), 1 (5%) a partial response (hemoglobin difference 2.1 g/dl) and 4 no response (mean hemoglobin difference 0.4 ± 1.8 g/dl) with a need for blood transfusions in a single patient. In the second study phase erythropoietin was highly effective in previous nonresponders (mean hemoglobin difference 3.3 ± 1.9 g/dl). The single patient with partial response had a minor hemoglobin increase (hemoglobin difference 1.0 g/dl). Conclusion: Most patients with ulcerative colitis-associated anemia improve on intravenous iron alone. Erythropoietin is effective in those who do not respond.
Journal Section:
Original Paper: Inflammatory Bowel Diseases
References
1.
Truelove SC, Witts LJ: Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 1955;2:1041.
2.
Beal RW, Skyring AP, McRae J, Firkin BG: The anemia of ulcerative colitis. Gastroenterology 1963;45:589–603.
3.
Both H, Torp-Pedersen K, Kreiner S, Hendriksen C, Binder V: Clinical appearance at diagnosis of ulcerative colitis and Crohn’s disease in a regional patient group. Scand J Gastroenterol 1983;18:987.
[PubMed]
4.
Yates P, Macht M, Williams NA, Elson CJ: Red cell autoantibody production by colonic mononuclear cells from a patient with ulcerative colitis and autoimmune haemolytic anaemia. Br J Haematol 1992;82:753–756.
[PubMed]
5.
Kaplinsky N, Frankl O: Salicylazosulphapyridine-induced Heinz body anemia. Acta Haematol 1978;59:310–314.
[PubMed]
6.
Ormerod TP: Observations on the incidence and cause of anaemia in ulcerative colitis. Gut 1967;8:107–114.
[PubMed]
7.
Means RT, Krantz SB: Progress in understanding the pathogenesis of anemia of chronic disease. Blood 1992;80:1639–1647.
[PubMed]
8.
Faquin WC, Schneider TJ, Goldberg MA: Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992;79:1987–1994.
[PubMed]
9.
Jelkmann W, Pagel H, Wolff M, Fandrey J: Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. Life Sci 1992;50:301–308.
[PubMed]
10.
Jelkmann W, Fandrey J, Frede S, Pagel H: Inhibition of erythropoietin production by cytokines – Implications for the anemia involved in inflammatory states. Ann NY Acad Sci 1994;718:300–309.
[PubMed]
11.
Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL: Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322:1689–1692.
[PubMed]
12.
Baer AN, Dessypris EN, Goldwasser E, Krantz SB: Blunted erythropoietin response to anaemia in rheumatoid arthritis. Br J Haematol 1987;66:559–564.
[PubMed]
13.
Hochberg MC, Arnold CM, Hogans BB, Spivak JL: Serum immunoreactive erythropoietin in rheumatoid arthritis: Impaired response to anemia. Arthritis Rheum 1988;31:1318–1321.
[PubMed]
14.
Gasche C, Reinisch W, Lochs H, Parsaei B, Bakos S, Wyatt J, Fueger GF, Gangl A: Anemia in Crohn’s disease: Importance of inadequate erythropoietin production and iron deficiency. Dig Dis Sci 1994;39:1930–1934.
[PubMed]
15.
Johannsen H, Jelkmann W, Wiedemann G, Otte M, Wagner T: Erythropoietin/haemoglobin relationship in leukaemia and ulcerative colitis. Eur J Haematol 1989;43:201–206.
[PubMed]
16.
Schreiber S, Howaldt S, Schnoor M, Nikolaus S, Bauditz J, Gasche C, Lochs H, Raedler A: Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med 1996;334:619–623.
[PubMed]
17.
Babbs C: Oxygen radicals in ulcerative colitis. Free Radic Biol Med 1992;13:169–181.
[PubMed]
18.
Adamson J, Eschbach JW: Treatment of anemia of chronic renal failure with recombinant human erythropoietin. Annu Rev Med 1990;41:349–360.
[PubMed]
19.
Miller CB, Platanias LC, Mills SR, Zahurak ML, Ratain MJ, Ettinger DS, Jones RJ: Phase I–II trial of erythropoietin in the treatment of cisplatin-associated anemia. J Natl Cancer Inst 1992;84:98–103.
[PubMed]
20.
Horina JH, Petritsch W, Schmid CR, Reicht G, Wenzl H, Silly H, Krejs GJ: Treatment of anemia in inflammatory bowel disease with recombinant human erythropoietin: Results in three patients. Gastroenterology 1993;104:1828–1831.
[PubMed]
21.
Gasche C, Dejaco C, Waldhoer T, Tillinger W, Reinisch W, Fueger GF, Gangl A, Lochs H: Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial. Ann Intern Med 1997;126:782–787.
[PubMed]
22.
Rachmilewitz D: Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomised trial. BMJ 1989;298:82–86.
[PubMed]
23.
Schlageter MH, Toubert ME, Podgorniak MP, Najean Y: Radioimmunoassay of erythropoietin: Analytical performance and clinical use in hematology. Clin Chem 1990;38:1731–1735.
24.
Bartels U, Strandberg Pedersen N, Jarnum S: Iron absorption and serum ferritin in chronic inflammatory bowel disease. Scand J Gastroenterol 1978;13:649–656.
[PubMed]
25.
Burns DL, Mascioli EA, Bistrian BR: Parenteral iron dextran therapy: A review. Nutrition 1995;11:163–168.
[PubMed]
26.
Nyvad O, Danielsen H, Madsen S: Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients. Lancet 1994;344:1305–1306.
27.
Sunder-Plassmann G, Hörl W: Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 1995;10:2070–2076.
[PubMed]
28.
Mercuriali F, Zanella A, Barosi G, Inghilleri G, Biffi E, Vinci A, Colotti MT: Use of erythropoietin to increase the volume of autologous blood donated by orthopedic patients. Transfusion 1993;33:55–60.
[PubMed]
29.
Mercuriali F, Gualtieri G, Sinigaglia L, Inghilleri G, Biffi E, Vinci A, Colotti MT, Barosi G, Lambertenghi Deliliers G: Use of recombinant human erythropoietin to assist autologous blood donation by anemic rheumatoid arthritis patients undergoing major orthopedic surgery. Transfusion 1994;34:501–506.
[PubMed]
30.
Simmonds NJ, Rampton DS: Inflammatory bowel disease – A radical view. Gut 1993;34:865–868.
[PubMed]
31.
Grisham MB, Granger DN: Neutrophil-mediated mucosal injury. Role of reactive oxygen metabolites. Dig Dis Sci 1988;33:6S–15S.
32.
Blake DR, Lunec J, Ahern M, Ring EF, Bradfield J, Gutteridge JM: Effect of intravenous iron dextran on rheumatoid synovitis. Ann Rheum Dis 1985;44:183–188.
[PubMed]
33.
Winyard PG, Blake DR, Chirico S, Gutteridge JM, Lunec J: Mechanism of exacerbation of rheumatoid synovitis by total-dose iron-dextran infusion: In vivo demonstration of iron-promoted oxidant stress. Lancet 1987;i:69–72.
34.
Conell WR, Kamm MA, Ritchie JK, Lennard-Jones JE: Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993;34:1081–1085.
[PubMed]
35.
Van Wyck DB, Stivelman JC, Ruiz J, Kirlin LF, Katz MA, Ogden DA: Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int 1989;35:712–716.
[PubMed]
36.
Thomson ABR, Brust R, Ali MAN, Mant MJ, Valberg LS: Iron deficiency in inflammatory bowel disease. Dig Dis 1978;23:705–709.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
1999
You do not currently have access to this content.
